Seattle, WA (PRWEB) May 20, 2014
Quorum Review IRB, the industry leader in central IRB services, unveils today an improved process for reviewing Minimal Risk Research.
Quorum’s new Expeditable Research Review allows for faster turnaround time of minimal risk protocols: Next day for qualifying minimal risk protocols with no consent forms or recruitment materials, and four days for those with consent forms and/or recruitment materials. The service also features a special discounted pricing.
As Quorum Review CEO Cami Gearhart, JD, explains, this service provides a customized approach to research studies that are designed to involve no greater than minimal risk to study subjects. “Our Expeditable Research Review process has been improved to reflect the different nature of minimal risk protocols. Through our updated internal processes, we are able to provide a more efficient review timeline to our clients.”
The service is of notable interest to researchers hoping to engage in observational registry or data collection studies or those involving minimally invasive procedures. More information on the revamped Expeditable Research Review and all of Quorum’s ethics review services can be found at http://www.QuorumReview.com/quorum-advantage.
About Quorum Review
Quorum Review is an independent ethics review board fully accredited by the Association for the Accreditation of Human Research Protection Programs (AAHRPP), and has been providing ethics review of drug and device trials since 1992. Quorum oversees research in accordance with U.S. and Canadian human research subject protection regulations and guidelines set forth by the International Committee on Harmonisation (ICH) and principles of the Belmont Report.
Quorum’s best-in-class service and support includes 15 Board meetings each week plus expedited review, 24 hour site review turnaround, 36 hour amendment review turnaround, a secure web portal, and SmartForms for online submissions. Quorum’s service offerings include full study review in the US, as well as internationally, a specialized Phase I team, institution specific support, and efficient processes for minimal risk studies.